Testosterone effect on growth and growth mediators of the GH–IGF-I axis in the liver and epiphyseal growth plate of juvenile rats

A Zung1, M Phillip2, S A Chalew3, T Palese4, A A Kowarski4 and Z Zadik1

1Pediatric Endocrine Unit, Kaplan Medical Center, Affiliated with Hadassah Medical School, The Hebrew University, Jerusalem, Israel
2Institute of Pediatric and Adolescent Endocrinology, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel
3Department of Endocrinology, Children’s Hospital and Louisiana State University Medical Center, New Orleans, Louisiana, USA
4Division of Pediatric Endocrinology, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA

(Requests for offprints should be addressed to A Zung, Pediatric Endocrine Unit, Kaplan Medical Center, Rehovot, Israel 76100)

ABSTRACT

Several studies have suggested that testosterone may have a direct, GH-independent effect on growth. In order to assess possible mechanism(s) whereby testosterone exerts its growth-promoting effect, we evaluated its effect on growth mediators of the GH–IGF-I axis, in both the liver and the epiphyseal growth plate (EGP). Testosterone was administered to peripubertal rats and the responses of mRNA of GH receptor, IGF-I, IGF-I receptor and IGF-binding proteins-1 and -3 (IGFBP-1 and IGFBP-3) as well as circulating IGF-I were evaluated in two time-related models: over 12 h after a single injection (short-term study) and 10 days after continuous administration (long-term study). Rats in the short-term study were castrated and were killed 1, 4, 6 and 12 h post injection. Rats in the long-term study were divided into two groups: castrated vs castrated and hypophysectomized, in order to assess the effect of testosterone in the presence and absence of GH. mRNA levels were determined by RNase protection assay, and serum IGF-I by RIA.

Testosterone enhanced weight gain in the rats treated for 10 days, a change that was similar in the presence or absence of GH. This effect was relatively small, however, by comparison with the total weight gained without testosterone. Testosterone had no effect on hepatic IGF-I mRNA abundance but induced a reduction in circulating IGF-I levels, in both the short- and long-term study. Testosterone had no effect on hepatic GH receptor and IGFBP-3 mRNA levels but resulted in a transient, short-term elevation in IGFBP-1 mRNA levels that was maximal 4 h post injection.

In the EGP, neither testosterone administration nor hypophysectomy had any effect on IGF-I and IGF-I receptor mRNA levels. However, testosterone increased GH receptor mRNA abundance after 10 days of continuous administration in hypophysectomized rats only.

These data suggest that the effect of testosterone on growth (as assessed by weight gain) is small and is not mediated by changes in hepatic gene expression of IGF-I, IGF-I receptor, IGFBP-1, IGFBP-3 or circulating IGF-I. At the EGP, the testosterone effect on linear growth is not mediated through changes in mRNA abundance of IGF-I and IGF-I receptor. The small but significant elevation of GH receptor mRNA levels in hypophysectomized rats may suggest a testosterone-mediated augmentation of a GH effect at the target organ.

Journal of Molecular Endocrinology (1999) 23, 209–221

INTRODUCTION

Normal puberty is accompanied by a dramatic increase in the rate of linear growth. The pubertal growth spurt in humans, secondary in magnitude only to the linear growth during the first 2 years of life, is associated with an increase in plasma
concentrations of sex steroids, insulin-like growth factor-I (IGF-I) and growth hormone (GH) (Thompson et al. 1972, Maurus et al. 1987). While it is well established that gonadal steroids influence body growth (Attie et al. 1990, Keenan et al. 1993), the precise role of testosterone in the pubertal growth spurt in males is not fully understood. Many studies have postulated that testosterone exerts its growth-promoting effect by enhancing the secretory pattern of GH (Martin et al. 1979), which in turn stimulates longitudinal bone growth either via hepatic IGF-I secretion (the somatomedin hypothesis) (Daughaday et al. 1972) or directly at the site of the epiphyseal growth plate (EGP), probably through local production of IGF-I (Isgaard et al. 1988). This indirect effect of testosterone is supported by the observation that testosterone exerts no significant increase in body length in the absence of GH, e.g., in hypophysectomized rats (Simpson et al. 1944, Scow 1952, Jansson et al. 1983).

Several lines of evidence, however, have suggested a GH-independent or synergistic effect (with GH) of testosterone on longitudinal bone growth. Growth acceleration has been reported during puberty in children with GH deficiency due to CNS lesions (Attie et al. 1990) or in children with GH insensitivity syndrome (Laron et al. 1980). Similarly, patients with complete GH deficiency due to GH gene deletion showed growth acceleration in response to treatment with anabolic steroids (Rivarola et al. 1984). These examples demonstrate the capacity of testosterone to stimulate growth, independent of GH or its action. Studies performed in hypophysectomized rats have shown a synergism of testosterone with GH in promoting somatic growth (Simpson et al. 1944, Klindt et al. 1990) or tibial EGP growth (Geschwind & Li 1955). The mechanism(s) whereby testosterone induces these changes is the subject of the present study. Some clinical data proposed that sex steroids may enhance IGF-I levels (Cara 1989), but recent studies have shown no effect of testosterone on hepatic IGF-I mRNA expression or circulating IGF-I levels in hypophysectomized rats (Phillip et al. 1992, Sahlin et al. 1994). Alternatively, testosterone may modulate the effect of IGF-I either through its binding proteins or its receptor at the target organs. IGF-I-binding proteins (IGFBPs) regulate the availability of IGF-I and so may modulate the biological activity of IGF-I in vivo (Baxter 1991). Likewise, changes in IGF-I receptor abundance may modulate its growth-promoting effect. IGF-I receptors are present in many target organs including cartilage (Isaksson et al. 1987). Another component of the GH–IGF-I axis that may be affected by testosterone and mediate its growth-promoting effect is GH receptor. GH receptor levels are sensitive to gonadal steroids, but data from previous studies on the nature of this effect are contradictory. Testosterone administration induced an elevation in hepatic GH receptor mRNA levels in rabbits (Yu et al. 1996), a decrease in GH-binding protein (GHBP) in man (Postel-Vinay et al. 1991) and no change in hepatic GH receptor mRNA or circulating GHBP in rats (Carmignac et al. 1993).

The purpose of this study was to investigate simultaneously the direct effect of testosterone on growth and growth mediators along the GH–IGF-I axis in the absence and presence of GH. We evaluated the response to testosterone administration in both liver and EGP, in order to elucidate possible endocrine or autocrine/paracrine mechanisms that account for its growth-promoting effect. Since steroid hormone may induce changes in mRNA levels within a range of minutes to several hours (Rories & Spelsberg 1989), we evaluated the effect of testosterone in two experimental time-models: over 12 h and 10 days after testosterone administration.

**MATERIALS AND METHODS**

**Animals**

*Short-term study* Forty-eight male Sprague–Dawley rats, 80–105 g body weight (BW), 28 days old (i.e., just prior to onset of normal puberty), were castrated by the supplier (Zivic-Miller, Allison Park, PA, USA) at least 2 days before the study. The animals were weighed on admission and divided into four groups of 12 rats each. Rats in each group were matched by weight and assigned to one of two subgroups, receiving either lipid vehicle (control subgroup) or testosterone (Sigma Chemical Company, St Louis, MO, USA) 100 µg/100 g BW, by a single s.c. injection (testosterone subgroup). The four groups of animals were killed 1, 4, 6 or 12 h post injection by CO₂ inhalation and decapitation.

*Long-term study* A first group of 18 male Sprague–Dawley rats was castrated by the supplier at 28 days of age (castrated group). A second group of 24 rats of the same type and age was castrated and hypophysectomized (hypophysectomized group). To ensure an adequate hypophysectomy, these animals were followed up for 7 days, with freely available standard laboratory chow and salt-supplemented water containing 9·0 g/l NaCl. Only
animals that demonstrated a weight gain of less than 1 g/day over the follow-up period were considered to be adequately hypophysectomized.

Rats in both groups were implanted with a 30 mm long Silastic capsule (Dow-Corning, Midland, MI, USA) s.c. at the sternum area, either at the time of castration (castrated group) or after 7 days of follow-up (hypophysectomized group). Half of the animals received an empty capsule, serving as controls, while the other half received capsules filled with crystalline testosterone. The capsules were incubated in saline for 48 h prior to implantation to initiate sex steroid diffusion, and to eliminate the elevated steroid levels often observed upon implantation of freshly prepared (unincubated) capsules (Park & Selmanoff 1993). The testosterone capsules were shown to maintain normal, unstimulated levels of luteinizing hormone in castrated male rats (Damassa et al. 1976). Both castrated and hypophysectomized rats were kept in holding cages for 10 days in diet conditions mentioned above. Six out of 24 hypophysectomized rats were excluded from the study due to inadequate hypophysectomy or initial weight well beyond the average weight of the group. Hence, control and testosterone-treated rats of both castrated and hypophysectomized groups had similar weights at the beginning of the study.

The hypophysectomized animals received replacement therapy consisting of 50 µg/100 g BW hydrocortisone (Upjohn Co., Kalamazoo, MI, USA) and 1 µg/100 g BW levothyroxine sodium (LyphoMed, Inc., Rosemont, IL, USA), given as daily s.c. injection over 10 days of the study. The animals were killed on the 11th day by CO₂ inhalation and decapitation.

Livers were removed from all rats, in both the short- and long-term studies, and immediately frozen in liquid nitrogen. Similarly, the EGP of each tibia was carefully removed under a magnifying device and frozen. All samples were stored at −70 °C until processing.

Animal protocols were approved by the University of Maryland School of Medicine Institutional Animal Care and Use Committee.

### RIA of IGF-I

Serum IGF-I concentrations were measured by specific RIA (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). For separating IGF-I from its binding protein, an acid-ethanol precipitation technique was used (Daughaday et al. 1980). The intra- and interassay coefficients of variation were 2 and 13.9% respectively.

### RNA preparation

Frozen samples of liver were homogenized using a Sybron polytron (Brinkmann, Westbury, NY, USA) in a guanidinium isothiocyanate (GIT) solution (RNAzol, Cinna/Biotech, Friendswood, TX, USA), followed by phenol/chloroform extraction and 2-propanol precipitation. Total RNA was prepared from the EGP by a method described previously (Heinrichs et al. 1994). Briefly, each frozen EGP sample (50–100 µg) was homogenized in GIT/sodium citrate/mercaptoethanol solution. The sample was then digested by Tris- HCl/proteinase K, extracted with phenol/chloroform and precipitated in sodium acetate/chloroform solution at −20 °C. After centrifugation, the pellet was resuspended in water and 8 M LiCl, precipitated overnight, and finally suspended in Tris-EDTA.

The RNA concentration was determined by measuring the absorbence at 260 nm. The integrity of the RNA was assessed by visual inspection of the ethidium bromide-stained 28S and 18S rRNA bands after electrophoresis through 1:25% agarose/2:2 M formaldehyde gels.

### Antisense RNA probes

**IGF-I** The rat 376 bp probe encoded part of the A domain, the entire D and E domain, and part of the 3’-untranslated region (UTR) of genomic IGF-I. The probe was linearized with HindIII and gel purified before the synthesis of antisense RNA with T7 RNA polymerase. Upon hybridization with the full-length IGF-I mRNA, this antisense RNA recognizes two alternatively spliced sequences, due to the presence (IGF-I Eb) or absence (IGF-I Ea) of a 52 base insert in the region coding for the E domain (Lowe et al. 1988).

**GH receptor** The rat GHR template was linearized with BamHI, gel purified, and transcribed with T7 RNA polymerase to generate a 445 bp antisense RNA probe. This probe produces two protected bands when hybridized with total RNA: a 439 base band corresponding to GHR mRNA, and a 298 base band corresponding to the alternatively spliced mRNA which encodes the GHBP (Mathews et al. 1989).

**IGF-I receptor** A 265 bp EcoRI-RsaI fragment was isolated from one of the rat IGF-I receptor cDNA clones and subcloned into the plasmid pGEM-3. The resulting construct was linearized with EcoRI and gel purified before the synthesis of antisense RNA with SP6 RNA polymerase. Hybridization of this probe with total RNA resulted in a protected band of 265 bases (Werner et al. 1989).
IGFBP-1 A 203 bp XmaI-AccI fragment derived from a rat IGFBP-1 cDNA was subcloned into the plasmid pGEM-4Z. This construct was then linearized with EcoRI and transcribed with T7 RNA polymerase. On hybridization with total RNA, this probe resulted in a protected band of 203 bp (Phillip et al. 1994).

IGFBP-3 The probe was generated by subcloning an HincII-AluI fragment of the corresponding cDNA into a pGEM-4Z plasmid. After linearization with ACCI, it was transcribed with T7 RNA polymerase (Ricciarelli et al. 1992).

pT7 18S RNA A complementary 18S rRNA probe was used as an internal control to establish the relative amount of RNA in each sample. Upon hybridization with total RNA, the HindIII-linearized 109 bp template (Ambion Inc., Austin, TX, USA) produces an 80 base band, corresponding to 18S rRNA. In order to achieve at least 5-fold molar excess of the antisense probe over the highly abundant target 18S rRNA, a MEGAscript T7 (Ambion Inc.) was used for the transcription reaction.

Solution hybridization/RNase protection assay

The solution hybridization/RNase protection assay were performed as previously described (Lowe et al. 1988). Briefly, 20 µg total RNA were hybridized with 200000 c.p.m. [32P]UTP-labeled antisense probes, and simultaneously with 1·4 µg pT7 RNA 18S probe as an internal control. The hybridization was carried out for 16 h at 45 °C in 75% formamide-0·4 M NaCl, followed by digestion with 40 µg/ml RNase-A and 2 µg/ml RNase T1. Protected hybrids were precipitated, denatured and electrophoresed through 8% polyacrylamide–urea gels. Gels were exposed to Kodak X-Omat AR film (Eastman Kodak, Rochester, NY, USA) at −70 °C with two intensifying screens. Protected bands on the autoradiograph were scanned using a scanning densitometer (Molecular Dynamics, Sunnyvale, CA, USA). The scanning results were analyzed by ImageQuant software (Molecular Dynamics), and the integrated volume of each band was corrected for the integrated volume of the corresponding 18S rRNA band. Each sample was assayed at least twice and the mean of the replicates was used for data analysis.

Statistical analysis

mRNA levels were expressed as a percentage of the control in each assay. The differences between means of the control and testosterone-treated groups were assessed by Student’s t-test. Data were analyzed using SigmaStat and SigmaPlot software (Jandel Scientific, San Rafael, CA, USA).

RESULTS

Changes in animal weights

Changes in weight were evaluated in the long-term study. Mean weights of the castrated rats, a day after castration and tube implantation, were 83·9 ± 4·4 (s.d.) and 81·1 ± 4·5 g for control and testosterone-treated animals respectively (P=NS). Weights were more than doubled over 10 days of follow-up in both subgroups, but in testosterone-treated animals final weights were significantly higher than weights in the control group (183·5 ± 10·4 vs 170·6 ± 10·4 g respectively, P=0·022) (Table 1), as well as the percentage change in weight (126·3 ± 7·1 vs 103·3 ± 6·9% in control group, P<0·001).

In the hypophysectomized group, 9 days after hypophysectomy and 2 days after tube implantation, the initial weights were similar in control and testosterone-treated rats. Ten days later, weight change was statistically significant only in testosterone-treated animals (91·4 ± 2·7 g initial weight vs 100·8 ± 5·5 g final weight after 10 days, P<0·001) (Table 1). Similar to the castrated

| Table 1. Body weights (g ± s.d.) of castrated and hypophysectomized rats in control and testosterone-treated (test) groups on the first day of the study (first) and 10 days later (last) |
|-------------|-------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|             | Castrated   | Hypophysectomized |             |             |             |             |
|             | First       | Last            | P value       | First       | Last            | P value       |
| Control     | 83·9 ± 4·4  | 170·6 ± 10·4    | <0·001        | 88·6 ± 4·0  | 91·6 ± 3·5     | NS            |
| Test        | 81·1 ± 4·5  | 183·5 ± 10·4    | <0·001        | 91·4 ± 2·7  | 100·8 ± 5·5    | <0·001        |
| P value     | NS          | 0·022           |              | NS          | <0·001         |              |
animals, mean final weight of hypophysectomized rats treated with testosterone was significantly higher than the corresponding mean weight of the control group (100.8 ± 5.5 vs 91.6 ± 3.5 g respectively, P = 0.001) (Table 1) and so was the percentage change in weight gain (10.1 ± 3.8 vs 3.6 ± 6.9% respectively, P = 0.024).

**Serum IGF-I levels**

In the long-term study, serum IGF-I concentrations were markedly reduced in response to hypophysectomy, and were in the range 1–2% of IGF-I levels measured in pituitary-intact rats. In castrated rats receiving testosterone for 10 days, serum IGF-I concentrations were significantly lower than corresponding levels in the control group (801 ± 115 vs 936 ± 48 ng/ml respectively, P = 0.005), whereas no effect of testosterone was noted in the hypophysectomized group. This negative effect of testosterone was already observed after a short exposure to testosterone: in the short-term study, the average serum IGF-I concentration of all testosterone-treated animals combined was significantly lower than corresponding value in controls (679 ± 139 vs 775 ± 132 ng/ml respectively, P = 0.022).

**IGF-I mRNA**

No changes were observed in IGF-I mRNA levels in response to short-term exposure to testosterone (up to 12 h) in liver or EGP tissues. In the long-term study, the effect of GH deficiency (i.e. hypophysectomy with hydrocortisone and levothyroxine supplements) was assessed in the control hypophysectomized vs control castrated animals. Mean mRNA values in the control castrated rats were defined as 100, with the corresponding s.d. for each transcript. Hepatic IGF-I mRNA levels were reduced 25-fold in control hypophysectomized rats compared with control castrated rats (4.1 ± 3.2 vs 100.0 ± 15.0 for IGF-I Ea and 4.2 ± 2.0 vs 100.0 ± 15.3 for IGF-I Eb transcripts respectively, both P < 0.001) (Fig. 1). By contrast, hypophysectomy had no effect on IGF-I mRNA levels in the EGP (Fig. 2).

Testosterone administration for 10 days had no effect on hepatic and EGP IGF-I mRNA levels, either in the absence (hypophysectomized group) or presence (castrated group) of GH (Fig. 3 for liver; Figs 2 and 4 for EGP). As shown in Fig. 2, the overall IGF-I mRNA levels in the EGP were much lower than corresponding levels in the liver, in both intact and hypophysectomized rats.

**GH receptor/GHBP mRNA**

In the short-term study, testosterone had no effect on GH receptor or GHBP mRNA levels, either in the liver or in the EGP. In the long-term study, hypophysectomy (in control hypophysectomized rats) induced a small (30–40%) but significant reduction in hepatic mRNA levels compared with the control castrated group, in both GH receptor (69.7 ± 27.8 vs 100.0 ± 19.3 respectively, P = 0.016) and GHBP (60.3 ± 32.2 vs 100.0 ± 24.6 respectively, P = 0.01) (Fig. 1). Similar to IGF-I mRNA levels, no changes were observed in GH receptor or GHBP mRNA levels after hypophysectomy in the EGP (Fig. 2). There were no changes in GH receptor and GHBP hepatic mRNA levels after testosterone administration for 10 days, in both castrated and hypophysectomized animals (Fig. 3). Similarly, no changes were observed in both mRNA transcripts in the EGP after testosterone administration in the castrated rats (Figs 4 and 5). In the hypophysectomized group, however, there was a small but significant increase in EGP GH receptor mRNA levels in testosterone-treated rats compared with controls (141.2 ± 15.8 vs 100.0 ± 13.0 respectively, P = 0.004) (Fig. 5). The increase in GHBP mRNA was not statistically significant (P = 0.063).

As shown in Fig. 2, mRNA levels of both GH receptor and GHBP in the EGP were remarkably lower than corresponding mRNA levels in the liver.

**IGF-I receptor mRNA**

IGF-I receptor mRNA was not detected in liver tissue but only in EGP (Fig. 2). In the short-term study, testosterone had no effect on IGF-I receptor mRNA abundance in the EGP. Neither hypophysectomy (Fig. 2) nor testosterone administration for 10 days (Figs 4 and 5) induced any effect on IGF-I receptor mRNA levels in the EGP.

**IGFBP-1 and -3 mRNA**

Unlike the absence of short-term effect of testosterone on other mRNA transcripts assessed in this study, hepatic IGFBP-1 mRNA levels were increased by 2- to 3-fold in the testosterone-treated group compared with that in the control group in the short-term study (Fig. 6). The change in mRNA levels was highly significant 4 h post testosterone injection (265.7 ± 63.0 vs 100.0 ± 68.0 in control, P < 0.001) and approached statistical significance (P = 0.07) at both 1 and 12 h time-points (Fig. 6). This effect was transient, however, as no change in hepatic IGFBP-1 mRNA levels in response to testosterone was observed in the long-term study.
 RNase protection assay of liver RNA samples in castrated vs castrated and hypophysectomized rats. Twenty micrograms total RNA samples were hybridized with GH receptor (GHR) and IGF-I riboprobes (upper left panel) and IGFBP-1 and IGFBP-3 riboprobes (upper right panel), simultaneously with 18S rRNA which served as an internal control. mRNA samples were obtained after 10 days of follow-up. The arrows to the right indicate the position of the protected bands. In the upper left panel, these arrows indicate two alternatively spliced IGF-I (Ea and Eb, see Methods) and two alternatively spliced GHR bands, corresponding to GHR and GHBP. The arrows to the left indicate the position of the antisense probes, digested with (probe + RNase) or without (probe − RNase) RNases. The effect of hypophysectomy on hepatic mRNA levels of IGF-I, GHR, IGFBP-1 and IGFBP-3 is presented in the lower panel. mRNA levels in castrated, pituitary intact animals (hatched bars) were defined as 100 for each transcript and compared with corresponding levels in hypophysectomised rats (open bars). Although depicted on the same scale, the different transcripts are compared only with their relative controls and not with each other. Each bar represents the mean ± S.E.M. of nine animals. *P<0.001; #P<0.02.

FIGURE 1. RNase protection assay of liver RNA samples in castrated vs castrated and hypophysectomized rats.
Testosterone had no effect on hepatic IGFBP-3 mRNA levels over 12 h or 10 days post injection, in both castrated and hypophysectomized groups (Figs 3 and 6).

Hypophysectomy resulted in a 6.6-fold decrease in the abundance of hepatic IGFBP-3 mRNA and a diametrically opposed effect (2.5-fold increase) in hepatic IGFBP-1 mRNA levels (Fig. 1).

IGFBP-1 and -3 mRNA were not assessed in the EGP due to limited amounts of total RNA obtained from this tissue.

**DISCUSSION**

Testosterone has a GH-independent effect on growth (presented as weight gain) in juvenile male rats, an effect we found to be relatively small by comparison with the growth-promoting effect of GH. The contribution of testosterone to weight gain was similar in the presence (castrated group) or absence (hypophysectomized group) of GH, and hence cannot be attributed to testosterone-induced GH secretion (Martin et al. 1979) or derived from a synergism between testosterone and GH (Simpson et al. 1944, Klindt et al. 1990). Our results are in agreement with those of Simpson et al. (1944), but in contrast to others, who found that weight gain in response to testosterone was substantially higher in the presence of GH, suggesting that GH may mediate the effect of testosterone on weight (Scow 1952, Jansson et al. 1983).

While the growth-promoting effect of testosterone has been shown in humans (Attie et al. 1990, Keenan et al. 1993), and supported by observations on its direct effect on rabbit epiphyseal articular chondrocytes (Corvol et al. 1987) and rat tibial EGP width (Ren et al. 1989), the precise mechanism(s) of testosterone action is elusive. We found no change in hepatic IGF-I mRNA levels in response to testosterone administration, either over 12 h post injection, or after 10 days of continuous exposure to testosterone. As expected, GH deficiency induced a remarkable decrease in hepatic IGF-I mRNA levels.
(Roberts et al. 1986), which was not affected by testosterone. Even in pituitary-intact animals, however, hepatic IGF-I mRNA levels remained unchanged in response to testosterone, suggesting that testosterone neither stimulated the secretion of GH nor acted synergistically with GH to stimulate hepatic IGF-I transcription. These findings extend a previous study, where no effect of testosterone on hepatic IGF-I mRNA was found in hypophysectomized male rats treated for only 5 days by daily injections of testosterone (Phillip et al. 1992). In this study, however, the effect of testosterone was not examined in pituitary-intact animals. In a different model comprising ovariectomized or hypophysectomized adult female rats (55–60 days old), no effect on hepatic IGF-I mRNA was found after testosterone administration for 7 days (Sahlin et al. 1994). Taken together, it is concluded that testosterone has no effect on hepatic IGF-I mRNA either in male or female rats, in both the presence or absence of GH. By contrast, we found significantly lower levels of circulating IGF-I in the testosterone-treated rats in both the short- and long-term studies. No change in circulating IGF-I levels was found in hypophysectomized rats, however, probably due to very low values of IGF-I in this group. In the same line of evidence, previous studies in male rats have shown an enhanced pubertal IGF-I surge 2 weeks after castration, an observation ascribed by Handelsman et al. (1987) to a restraining influence of testosterone on IGF-I production. Similarly, genetically hypogonadal mice and castrated guinea-pigs had an exaggerated pubertal IGF-I surge compared with intact animals (Beaune et al. 1992, Crawford et al. 1993), an effect that was normalized by testosterone administration (Crawford et al. 1993). In contrast to our findings in rats, testosterone administration to hypogonadal (Liu et al. 1987) and normal men (Hobbs et al. 1993), as well as to male adolescents with delayed puberty (Keenan et al. 1993), has been reported to increase circulating levels of IGF-I. The change in IGF-I concentration was associated with, and probably could be attributed to, an elevation in GH secretion (Albiston & Herington 1992), rather than to a direct effect of testosterone. Though speculative, the reduction in serum IGF-I levels in rats may mediate the stimulating effect of testosterone on GH secretion, since GH and IGF-I maintain negative feedback. It is conceivable that the negative effect of testosterone on circulating IGF-I levels in our study is post-transcriptional, as it was not preceded by a decrease in hepatic IGF-I mRNA.

In order to further elucidate the regulatory mechanism whereby testosterone reduced serum IGF-I levels, we simultaneously evaluated the effect
of testosterone on hepatic IGFBP-1 and -3. The liver is a major site of synthesis of both binding proteins (Albiston & Herington 1992), and IGFBP-3 is the predominant binding protein in rat and human sera. We found no effect of testosterone on hepatic mRNA levels of both binding proteins in the long-term study. Further study at the protein level is required, however, as circulating levels of IGFBP-3 would appear not to be primarily regulated at the level of mRNA abundance (Donovan et al. 1989). In the short-term study, testosterone had no effect on hepatic IGFBP-3 mRNA abundance, but induced a more than 2-fold increase in IGFBP-1 levels, a change that was most prominent 4 h post injection. This transient effect of testosterone was not observed in the long-term study, and may reflect the supraphysiological serum levels of testosterone obtained after a single injection. Serum testosterone levels peaked 30 min post injection, and after 2 h they were still 10-fold higher than reported levels gained by the implanted tube (data not shown) (Damassa et al. 1976). As previously reported (Blum & Ranke 1990), GH deficiency increased IGFBP-1 and decreased IGFBP-3 hepatic mRNA.

Another component in the GH–IGF-I axis that may mediate the testosterone-promoting effect on growth is GH receptor. Testosterone administration had no effect on hepatic mRNA levels of the two alternatively spliced transcripts of GH receptor and GHBP, in both the short- and long-term studies. This is in accord with Carmignac et al. (1993), who found that testosterone administration to GH-deficient rats had no effect on GHBP or GH receptor, nor did it affect their up-regulation by GH. Furthermore, they found that testosterone had no effect on hepatic mRNA levels of both transcripts, in both the presence or absence of GH (Carmignac et al. 1993). While examining the effect of GH deficiency on hepatic GH receptor and GHBP mRNA levels, we found a significant reduction in the abundance of both transcripts in hypophysectomized rats. The reported effect of hypophysectomy on liver GH receptor expression is somewhat contradictory. In male rats, no change (Mathews et al. 1989, Domene et al. 1993) or even an increase (Frick et al. 1990) in hepatic GH receptor mRNA was found after hypophysectomy. On the other hand, in female rats, hypophysectomy reduced GH receptor and GHBP mRNA levels by 30–35% (Maiter et al. 1992), very similar to the range of reduction found in the present study. The diversity in methods used in the previous studies may account for the different results. Unlike others, we used internal controls in each assay, which we found helpful in discriminating small changes in mRNA abundance. Alternatively, the reduction in GH receptor/GHBP mRNA may reflect a reduction in a subpopulation of hepatic GH receptor transcripts containing a specific 5′-UTR sequence, termed GHR1 (Baumbach & Bingham 1995). Hypophysectomy vastly reduced GHR1 mRNA expression (Baumbach & Bingham 1995) while GH administration increased its abundance in GH-deficient dwarf rats (Gabrielsson et al. 1995). This subclass of GH receptor/GHBP mRNA is expressed only in the liver (which may account for the absence of change of GH receptor mRNA in EGP) and is far more abundant in females, which may explain the results in female rats (Maiter et al. 1992). Although the determination of this subclass of GH receptor transcript requires specific probes, it is possible to observe some reduction in GH receptor/GHBP mRNA levels by using a probe directed against the coding sequence. The effect of hypophysectomy on GH receptor/GHBP mRNA may be augmented in our study, where a selection of only severely GH-deficient rats was made by a week-long follow-up of weight gain. Further
demonstration of this accurate selection comes from the measured serum IGF-I levels, reaching only 1–2% compared with those in pituitary-intact animals.

While the liver is the main source of growth mediators along the GH–IGF-I axis, EGP is considered the target organ for these mediators. Indeed, the action of IGF-I and GH in promoting long-bone growth is thought to be due to stimulation of EGP chondrocytes proliferation and/or hypertrophy. Although traditionally the GH effect on linear growth was thought to be mediated through the endocrine effect of circulating IGF-I (the somatomedin hypothesis) (Daughaday et al. 1972), several studies have suggested that GH stimulates local production of IGF-I at the EGP, which in turn regulates bone growth by an autocrine/paracrine mechanism (Isgaard et al. 1988). We examined the hypothesis that testosterone enhances growth via local production of IGF-I at the EGP. We also examined the hypothesis that testosterone induces bone growth by affecting the abundance of receptors for GH or IGF-I, rendering the target tissue more sensitive to their effect.

We found no change in EGP mRNA levels of both IGF-I and its receptor, either over 12 h or after 10 days of exposure to testosterone. In a previous study, five daily injections to a small group of hypophysectomized rats similarly yielded no effect on mRNA of IGF-I and its receptor at the EGP (Phillip et al. 1992). The high level of IGF-I receptor mRNA in EGP compared with liver expression emphasizes the important role of IGF-I in bone growth, as has been previously suggested (Guler et al. 1988). By contrast, IGF-I mRNA in the EGP was very low compared with corresponding levels in the liver. A qualitatively similar ratio of IGF-I protein between liver and cartilage in male rats was found by D'Ercole et al. (1984). Unlike its negative effect in the liver, hypophysectomy induced no change in mRNA levels of both IGF-I and IGF-I receptor at the EGP. This novel observation is supported by a previous report, where extractable IGF-I concentrations in different rat tissues were examined. In response to hypophysectomy, a significant reduction in liver IGF-I concentration was found, while IGF-I levels in the sternum cartilage remained unchanged (D’Ercole et al. 1984). It is conceivable that IGF-I is differentially regulated in a tissue-specific pattern, at both the mRNA and the protein level.

The only growth mediator we found to be regulated in the EGP by testosterone was GH receptor. GH receptor mRNA was mildly but significantly increased in response to testosterone administration for 10 days in the hypophysectomized rats only. A similar but quantitatively smaller effect was observed in male castrated rabbits, where
continuous testosterone administration over 21 days induced a 28% increase in GH receptor mRNA levels at the EGP (Yu et al. 1996). In the castrated group, where no effect of testosterone was observed, it is possible that the presence of GH counteracts the stimulating effect of testosterone on GH receptor mRNA levels. Testosterone-related up-regulation of GH receptor mRNA may reflect an indirect mechanism for bone growth through augmentation of the GH effect at the EGP. Unlike

**Figure 6.** Solution hybridization/RNase protection assay showing protected bands of three simultaneously expressed mRNAs in liver: IGFBP-1 and IGFBP-3 together with 18S rRNA which served as an internal control (upper panel). Twenty micrograms total hepatic RNA samples, obtained from castrated rats 1, 4, 6 and 12 h after a single injection of either testosterone (T) (100 µg/100 g BW) or lipid vehicle (control, C) were hybridized with 32P-labeled rat riboprobes. Each lane represents a single animal. The arrows to the right indicate the position of the protected bands. The arrows to the left indicate the position of the antisense RNA probes diluted 1:100 (native probe) or diluted 1:200 without RNases (probe – RNase). Lower panels show hepatic mRNA levels of IGFBP-1 (lower right) and IGFBP-3 (lower left) in the experiment described in the upper panel legend. mRNA levels of testosterone-treated rats (open bars) were compared with levels in the control group (hatched bars) defined as 100. Each bar represents the mean ± s.e.m. of six animals. *P=0·001 vs control.

*Journal of Molecular Endocrinology (1999) 23, 209–221*
ACKNOWLEDGEMENTS

This work was supported in part by a fellowship grant from the Genentech Foundation for Growth and Development and an Israel Ministry of Health Grant (Chief Scientist’s Office) (to A Z).

REFERENCES


Baumbach WR & Bingham B 1995 One class of growth hormone (GH) receptor and binding protein messenger ribonucleic acid in rat liver, GHRI, is sexually dimorphic and regulated by GH. Endocrinology 136 749–760.


